Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse modelopen access
- Authors
- El-Shemi, Adel Galal; Ashshi, Ahmad Mohammed; Na, Youjin; Li, Yan; Basalamah, Mohammed; Al-Allaf, Faisal Ahmad; Oh, Eonju; Jung, Bo-Kyeong; Yun, Chae-Ok
- Issue Date
- May-2016
- Publisher
- BMC
- Keywords
- Dual gene virotherapy; Oncolytic adenoviruses; Interleukin-12; Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL); Hepatocellular carcinoma
- Citation
- JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, v.35
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Volume
- 35
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/5603
- DOI
- 10.1186/s13046-016-0353-8
- ISSN
- 1756-9966
- Abstract
- Background: Gene-based virotherapy mediated by oncolytic viruses is currently experiencing a renaissance in cancer therapy. However, relatively little attention has been given to the potentiality of dual gene virotherapy strategy as a novel therapeutic approach to mediate triplex anticancer combination effects, particularly if the two suitable genes are well chosen. Both tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and interleukin-12 (IL-12) have been emerged as promising pharmacological candidates in cancer therapy; however, the combined efficacy of TRAIL and IL-12 genes for treatment of human hepatocellular carcinoma (HCC) remains to be determined. Methods: Herein, we investigated the therapeutic efficacy of concurrent therapy with two armed oncolytic adenoviruses encoding human TRAIL gene (Ad-Delta B/TRAIL) and IL-12 gene (Ad-Delta B/IL-12), respectively, on preclinical models of human HCC, and also elucidated the possible underlying mechanisms. The effects of Ad-Delta B/TRAIL+Ad-Delta B/IL-12 combination therapy were assessed both in vitro on Hep3B and HuH7 human HCC cell lines and in vivo on HCC-orthotopic model established in the livers of athymic nude mice by intrahepatic implantation of human Hep3B cells. Results: Compared to therapy with non-armed control Ad-Delta B, combined therapy with Ad-Delta B/TRAIL+Ad-Delta B/IL-12 elicited profound anti-HCC killing effects on Hep3B and HuH7 cells and on the transplanted Hep3B-orthotopic model. Efficient viral replication and TRAIL and IL-12 expression were also confirmed in HCC cells and the harvested tumor tissues treated with this combination therapy. Mechanistically, co-therapy with Ad-Delta B/TRAIL+Ad-Delta B/IL-12 exhibited an enhanced effect on apoptosis promotion, activation of caspase-3 and-8, generation of anti-tumor immune response evidenced by upregulation of interferon gamma (IFN-gamma) production and infiltration of natural killer-and antigen presenting cells, and remarkable repression of intratumor vascular endothelial growth factor (VEGF) and cluster of differentiation 31 (CD31) expression and tumor microvessel density. Conclusions: Overall, our data showed a favorable therapeutic effect of Ad-Delta B/TRAIL+Ad-Delta B/IL-12 combination therapy against human HCC, and may therefore constitute a promising and effective therapeutic strategy for treating human HCC. However, further studies are warranted for its reliable clinical translation.
- Files in This Item
-
- Appears in
Collections - 서울 공과대학 > 서울 생명공학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/5603)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.